Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 1/2019

01-07-2019 | Thyroid Cancer | Review

Advances in metabolomics of thyroid cancer diagnosis and metabolic regulation

Published in: Endocrine | Issue 1/2019

Login to get access

Abstract

Thyroid cancers (TCs) are the most frequent endocrine malignancy with an unpredictable fast-growing incidence, especially in females all over the world. Fine-needle aspiration biopsy (FNAB) analysis is an accurate diagnostic method for detecting thyroid nodules and classification of TC. Though simplicity, safety, and accuracy of FNAB, 15–30% of cases are indeterminate, and it is not possible to determine the exact cytology of the specimen. This demands the need for innovative methods capable to find crucial biomarkers with adequate sensitivity for diagnosis and prediction in TC researches. Cancer-based metabolomics is a vast emerging field focused on the detection of a large set of metabolites extracted from biofluids or tissues. Using analytical chemistry procedures allows for the potential recognition of cancer-based metabolites for the purposes of advancing the era of personalized medicine. Nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS) coupled with separation techniques e.g., gas chromatography (GC) and liquid chromatography (LC) are the main approaches for metabolic studies in cancers. The immense metabolite profiling has provided a chance to discover novel biomarkers for early detection of thyroid cancer and reduce unnecessary aggressive surgery. In this review, we recapitulate the recent advances and developed methods of diverse metabolomics tools and metabolic phenotypes of thyroid cancer, following a brief discussion of recent challenges in the thyroid cancer diagnosis.
Literature
1.
S. Vaccarella, S. Franceschi, F. Bray, C.P. Wild, M. Plummer, L. Dal Maso, Worldwide thyroid-cancer epidemic? the increasing impact of overdiagnosis. N. Engl. J. Med. 375, 614 (2016)CrossRefPubMed
2.
L.Z.K. Enewold, E. Ron, A.J. Marrogi, A. Stojadinovic, G.E. Peoples, S.S. Devesa, Rising thyroid cancer incidence in the United States by demographic and tumor characteristics. Cancer Epidemiol. Biomarkers. Prev. 18, 784–779 (2009)CrossRefPubMedPubMedCentral
3.
4.
F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J. Clin. 68, 394–424 (2018)
5.
G.D. Braunstein, Thyroid Cnacer. In: Melmed, editor. Endocrine Updates. Vol. 32 (Springer, NY, USA, 2012)
6.
N.R.M.E. Lemoine, F.S. Wyllie, C.J. Farr, D. Hughes, R.A. Padua et al., Activated ras oncogenes in human thyroid cancers. Cancer Res. 48, 4459–4463 (1998)
7.
D. Sarne, SA, External radiation and thyroid neoplasia. Endocrinol. Metab. Clin. North. Am. 25, 181–195 (1996)CrossRefPubMed
8.
H.N.I. Yamashita, S. Noguchi, N. Murakami, A. Moriuchi, S. Yokoyama et al., Thyroid carcinoma in benign thyroid diseases:an analysis from minute carcinoma. Acta Pathol. Jpn. 35, 781–788 (1985)PubMed
9.
American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer CD, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, F. Pacini, M. Schlumberger, S.I. Sherman, D.L. Steward, R.M. Tuttle, Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 19, 1167–1214 (2009)CrossRef
10.
E.S.A.S. Cibas, The Bethesda system for reporting thyroid cytopathology. Thyroid. 19, 1159–1165 (2009)CrossRefPubMed
11.
J. Yang, V. Schnadig, R. Logrono, P.G. Wasserman, Fine-needle aspiration of thyroid nodules: a study of 4703 patients with histologic and clinical correlations. Cancer 25 111, 306–315 (2007)CrossRef
12.
L. Yassa, E.S. Cibas, C.B. Benson, M.C. Frates, P.M. Doubilet, A.A. Gawande, F.D. Moore Jr, B.W. Kim, V. Nosé, E. Marqusee, Long‐term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer Cytopathol.: Interdisciplinary International Journal of the American Cancer Society 111, 508–516 (2007)CrossRef
13.
F. Pacini, M. Schlumberger, H. Dralle, R. Elisei, J.W. Smit, W. Wiersinga, Erratum: European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur. J. Endocrinol. 155, 385 (2006)CrossRef
14.
M. Bongiovanni, A. Spitale, W.C. Faquin, L. Mazzucchelli, Z.W. Baloch, The Bethesda system for reporting thyroid cytopathology: a meta-analysis. Acta Cytol. 56, 333–339 (2012)CrossRefPubMed
15.
A.S. Ho, E.E. Sarti, K.S. Jain, H. Wang, I.J. Nixon, A.R. Shaha, J.P. Shah, D.H. Kraus, R. Ghossein, S.A. Fish, Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS). Thyroid. 24, 832–839 (2014)CrossRefPubMedPubMedCentral
16.
X. Su, X. Jiang, X. Xu, W. Wang, X. Teng, A. Shao, L. Teng, Diagnostic value of BRAFV600E-mutation analysis in fine-needle aspiration of thyroid nodules: a meta-analysis. Onco. Targets Ther. 9, 2495 (2016)CrossRefPubMedPubMedCentral
17.
W. Clinkscales, A. Ong, S. Nguyen, E.E. Harruff, M.B. Gillespie, Diagnostic value of RAS mutations in indeterminate thyroid nodules: systematic review and meta-analysis. Otolaryngology–Head and Neck Surgery 156, 472–479 (2017)CrossRefPubMed
18.
M. Eszlinger, A. Krogdahl, S. Münz, C. Rehfeld, E.M. Precht Jensen, C. Ferraz, E. Bösenberg, N. Drieschner, M. Scholz, L. Hegedüs, Impact of molecular screening for point mutations and rearrangements in routine air-dried fine-needle aspiration samples of thyroid nodules. Thyroid. 24, 305–313 (2014)CrossRefPubMed
19.
S. Yu, Y. Liu, J. Wang, Z. Guo, Q. Zhang, F. Yu, Y. Zhang, K. Huang, Y. Li, E. Song, Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. The Journal of Clinical Endocrinology & Metabolism 97, 2084–2092 (2012)CrossRef
20.
S. Fischer, S.L. Asa, Application of immunohistochemistry to thyroid neoplasms. Arch. Pathol. Lab. Med. 132, 359–372 (2008)PubMed
21.
S. Serra, S.L. Asa, Controversies in thyroid pathology: the diagnosis of follicular neoplasms. Endocr. Pathol. 19, 156–165 (2008)CrossRefPubMed
22.
J.K. Nicholson, J.C. Lindon, E. Holmes, ‘Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29, 1181–1189 (1999)CrossRefPubMed
23.
W.M. Claudino, P.H. Goncalves, A. di Leo, P.A. Philip, F.H. Sarkar, Metabolomics in cancer: a bench-to-bedside intersection. Crit. Rev. Oncol. Hematol. 84, 1–7 (2012)CrossRefPubMed
24.
A. Shevchenko, K. Simons, Lipidomics: coming to grips with lipid diversity. Nat. Rev. Mol. Cell Biol. 11, 593 (2010)CrossRefPubMed
25.
26.
R. Bandu, H.J. Mok, K.P. Kim, Phospholipids as cancer biomarkers: mass spectrometry‐based analysis. Mass. Spectrom. Rev. 37, 107–138 (2018)CrossRefPubMed
27.
P. Miccoli, L. Torregrossa, L. Shintu, A. Magalhaes, J. Chandran, A. Tintaru, C. Ugolini, M.N. Minuto, M. Miccoli, F. Basolo, Metabolomics approach to thyroid nodules: A high-resolution magic-angle spinning nuclear magnetic resonance–based study. Surgery 152, 1118–1124 (2012)CrossRefPubMed
28.
A. Wojakowska, M. Chekan, P. Widlak, M. Pietrowska, Application of metabolomics in thyroid cancer research. Int. Jo. Endocrinol 2015, 258763 (2015)
29.
R.H. Grogan, E.J. Mitmaker, O.H. Clark, The evolution of biomarkers in thyroid cancer—from mass screening to a personalized biosignature. Cancers 2, 885–912 (2010)CrossRefPubMedPubMedCentral
30.
L. Guo, C. Wang, C. Chi, X. Wang, S. Liu, W. Zhao, C. Ke, G. Xu, E. Li, Exhaled breath volatile biomarker analysis for thyroid cancer. Translational Research 166, 188–195 (2015)CrossRefPubMed
31.
X. Shang, X. Zhong, X. Tian, Metabolomics of papillary thyroid carcinoma tissues: potential biomarkers for diagnosis and promising targets for therapy. Tumor Biology 37, 11163–11175 (2016)CrossRefPubMed
32.
M. Chen, M. Shen, Y. Li, C. Liu, K. Zhou, W. Hu, B. Xu, Y. Xia, W. Tang, GC-MS-based metabolomic analysis of human papillary thyroid carcinoma tissue. Int. J. Mol. Med. 36, 1607–1614 (2015)CrossRefPubMed
33.
G.N. Gowda, S. Zhang, H. Gu, V. Asiago, N. Shanaiah, D. Raftery, Metabolomics-based methods for early disease diagnostics. Expert. Rev. Mol. Diagn. 8, 617–633 (2008)CrossRefPubMed
34.
A. Scalbert, L. Brennan, O. Fiehn, T. Hankemeier, B.S. Kristal, B. van Ommen, E. Pujos-Guillot, E. Verheij, D. Wishart, S. Wopereis, Mass-spectrometry-based metabolomics: limitations and recommendations for future progress with particular focus on nutrition research. Metabolomics. 5, 435 (2009)CrossRefPubMedPubMedCentral
35.
36.
L. Brennan, NMR-based metabolomics: from sample preparation to applications in nutrition research. Prog. Nucl. Magn. Reson. Spectros. 83, 42–49 (2014)CrossRef
37.
J.L. Griffin, R.A. Kauppinen, Tumour metabolomics in animal models of human cancer. J. Proteome. Res. 6, 498–505 (2007)CrossRefPubMed
38.
I.C. Felli, B. Brutscher, Recent advances in solution NMR: fast methods and heteronuclear direct detection. Chemphyschem 10, 1356–1368 (2009)CrossRefPubMed
39.
P. Russell, C.L. Lean, L. Delbridge, G.L. May, S. Dowd, C.E. Mountford, Proton magnetic resonance and human thyroid neoplasia I: discrimination between benign and malignant neoplasms. Am. J. Med. 96, 383–388 (1994)CrossRefPubMed
40.
W.B. Mackinnon, L. Delbridge, P. Russell, C.L. Lean, G.L. May, S. Doran, S. Dowd, C.E. Mountford, Two-dimensional proton magnetic resonance spectroscopy for tissue characterization of thyroid neoplasms. World J. Surg. 20, 841–847 (1996)CrossRefPubMed
41.
Y. Yoshioka, J. Sasaki, M. Yamamoto, K. Saitoh, S. Nakaya, M. Kubokawa, Quantitation by 1H‐NMR of dolichol, cholesterol and choline‐containing lipids in extracts of normal and phathological thyroid tissue. NMR. Biomed. 13, 377–383 (2000)CrossRefPubMed
42.
A.D. King, D.K. Yeung, A.T. Ahuja, M. Gary, A.B. Chan, S.S. Lam, A.C. van Hasselt, In vivo 1H MR spectroscopy of thyroid carcinoma. Eur. J. Radiol. 54, 112–117 (2005)CrossRefPubMed
43.
K.W. Jordan, C.B. Adkins, L.L. Cheng, W.C. Faquin, Application of magnetic-resonance-spectroscopy-based metabolomics to the fine-needle aspiration diagnosis of papillary thyroid carcinoma. Acta Cytol. 55, 584–589 (2011)CrossRefPubMedPubMedCentral
44.
L. Torregrossa, L. Shintu, J. Nambiath Chandran, A. Tintaru, C. Ugolini, Magalhães Ar, F. Basolo, P. Miccoli, S. Caldarelli, Toward the reliable diagnosis of indeterminate thyroid lesions: a HRMAS NMR-based metabolomics case of study. J. Proteome. Res. 11, 3317–3325 (2012)CrossRefPubMed
45.
S. Deja, T. Dawiskiba, W. Balcerzak, M. Orczyk-Pawiłowicz, M. Głód, D. Pawełka, P. Młynarz, Follicular adenomas exhibit a unique metabolic profile. 1H NMR studies of thyroid lesions. PLoS ONE. 8, e84637 (2013)CrossRefPubMedPubMedCentral
46.
Y. Tian, X. Nie, S. Xu, Y. Li, T. Huang, H. Tang, Y. Wang, Integrative metabonomics as potential method for diagnosis of thyroid malignancy. Sci. Rep. 5, 14869 (2015)CrossRefPubMedPubMedCentral
47.
I. Ryoo, H. Kwon, S.C. Kim, S.C. Jung, J.A. Yeom, H.S. Shin, H.R. Cho, T.J. Yun, S.H. Choi, C.-H. Sohn, Metabolomic analysis of percutaneous fine-needle aspiration specimens of thyroid nodules: potential application for the preoperative diagnosis of thyroid cancer. Sci. Rep. 6, 30075 (2016)CrossRefPubMedPubMedCentral
48.
J. Lu, S. Hu, P. Miccoli, Q. Zeng, S. Liu, L. Ran, C. Hu, Non-invasive diagnosis of papillary thyroid microcarcinoma: a NMR-based metabolomics approach. Oncotarget 7, 81768 (2016)PubMedPubMedCentral
49.
W. Wojtowicz, A. Zabek, S. Deja, T. Dawiskiba, D. Pawelka, M. Glod, W. Balcerzak, P. Mlynarz, Serum and urine 1 H NMR-based metabolomics in the diagnosis of selected thyroid diseases. Sci. Rep. 7, 9108 (2017)CrossRefPubMedPubMedCentral
50.
J.W. Seo, K. Han, J. Lee, E.-K. Kim, H.J. Moon, J.H. Yoon, V.Y. Park, H.-M. Baek, J.Y. Kwak, Application of metabolomics in prediction of lymph node metastasis in papillary thyroid carcinoma. PLoS ONE. 13, e0193883 (2018)CrossRefPubMedPubMedCentral
51.
Y. Gu, T. Chen, S. Fu, X. Sun, L. Wang, J. Wang, Y. Lu, S. Ding, G. Ruan, L. Teng, Perioperative dynamics and significance of amino acid profiles in patients with cancer. J. Transl. Med. 13, 35 (2015)CrossRefPubMedPubMedCentral
52.
Z. Yao, P. Yin, D. Su, Z. Peng, L. Zhou, L. Ma, W. Guo, L. Ma, G. Xu, J. Shi, Serum metabolic profiling and features of papillary thyroid carcinoma and nodular goiter. Mol. Biosyst. 7, 2608–2614 (2011)CrossRefPubMed
53.
A. Wojakowska, M. Chekan, Ł. Marczak, K. Polanski, D. Lange, M. Pietrowska, P. Widlak, Detection of metabolites discriminating subtypes of thyroid cancer: molecular profiling of FFPE samples using the GC/MS approach. Mol. Cell. Endocrinol. 417, 149–157 (2015)CrossRefPubMed
54.
Y. Xu, X. Zheng, Y. Qiu, W. Jia, J. Wang, S. Yin, Distinct metabolomic profiles of papillary thyroid carcinoma and benign thyroid adenoma. J. Proteome. Res. 14, 3315–3321 (2015)CrossRefPubMed
55.
S. Shimma, Y. Sugiura, T. Hayasaka, N. Zaima, M. Matsumoto, M. Setou, Mass imaging and identification of biomolecules with MALDI-QIT-TOF-based system. Anal. Chem. 80, 878–885 (2008)CrossRefPubMed
56.
S. Ishikawa, I. Tateya, T. Hayasaka, N. Masaki, Y. Takizawa, S. Ohno, T. Kojima, Y. Kitani, M. Kitamura, S. Hirano, Increased expression of phosphatidylcholine (16: 0/18: 1) and (16: 0/18: 2) in thyroid papillary cancer. PLoS ONE. 7, e48873 (2012)CrossRefPubMedPubMedCentral
57.
S. Guo, Y. Wang, D. Zhou, Z. Li, Significantly increased monounsaturated lipids relative to polyunsaturated lipids in six types of cancer microenvironment are observed by mass spectrometry imaging. Sci. Rep. 4, 5959 (2014)CrossRefPubMedPubMedCentral
58.
S. Guo, L. Qiu, Y. Wang, X. Qin, H. Liu, M. He, Y. Zhang, Z. Li, X. Chen, Tissue imaging and serum lipidomic profiling for screening potential biomarkers of thyroid tumors by matrix-assisted laser desorption/ionization-Fourier transform ion cyclotron resonance mass spectrometry. Anal. Bioanal. Chem. 406, 4357–4370 (2014)CrossRefPubMed
59.
A. Wojakowska, L. Cole, M. Chekan, K. Bednarczyk, M. Maksymiak, M. Oczko-Wojciechowska, B. Jarzab, M. Clench, J. Polańska, M. Pietrowska, Discrimination of papillary thyroid cancer from non-cancerous thyroid tissue based on lipid profiling by MALDI-MSI. Endokrynologia Polska 69, 2–8 (2015)CrossRef
60.
O. Warburg, S. Minami, Versuche an überlebendem carcinom-gewebe. J. Mol. Med. 2, 776–777 (1923)
61.
62.
D.C. Ngo, K. Ververis, S.M. Tortorella, T.C. Karagiannis, Introduction to the molecular basis of cancer metabolism and the Warburg effect. Mol. Biol. Rep. 42, 819–823 (2015)CrossRefPubMed
63.
R.J. DeBerardinis, J.J. Lum, G. Hatzivassiliou, C.B. Thompson, The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell. Metab. 7, 11–20 (2008)CrossRefPubMed
64.
Y. Asgari, Z. Zabihinpour, A. Salehzadeh-Yazdi, F. Schreiber, A. Masoudi-Nejad, Alterations in cancer cell metabolism: the Warburg effect and metabolic adaptation. Genomics 105, 275–281 (2015)CrossRefPubMed
65.
R.G. Coelho, Jd.M. Cazarin, C. de Albuquerque, J.P. Albuquerque, B.M. de Andrade, D.P. Carvalho, Differential glycolytic profile and Warburg effect in papillary thyroid carcinoma cell lines. Oncol. Rep. 36, 3673–3681 (2016)CrossRefPubMed
66.
67.
U. Weyemi, B. Caillou, M. Talbot, R. Ameziane-El-Hassani, L. Lacroix, O. Lagent-Chevallier, A. Al Ghuzlan, D. Roos, J.-M. Bidart, A. Virion, Intracellular expression of reactive oxygen species-generating NADPH oxidase NOX4 in normal and cancer thyroid tissues. Endocr. Relat. Cancer 17, 27–37 (2010)CrossRefPubMed
68.
U. Weyemi, O. Lagente-Chevallier, M. Boufraqech, F. Prenois, F. Courtin, B. Caillou, M. Talbot, M. Dardalhon, A. Al Ghuzlan, J. Bidart, ROS-generating NADPH oxidase NOX4 is a critical mediator in oncogenic H-Ras-induced DNA damage and subsequent senescence. Oncogene 31, 1117 (2012)CrossRefPubMed
69.
N. Azouzi, J. Cailloux, J.M. Cazarin, J.A. Knauf, J. Cracchiolo, A. Al Ghuzlan, D. Hartl, M. Polak, A. Carré, M. El Mzibri, NADPH oxidase NOX4 is a critical mediator of BRAFV600E-induced downregulation of the sodium/iodide symporter in papillary thyroid carcinomas. Antioxid. Redox. Signal. 26, 864–877 (2017)CrossRefPubMedPubMedCentral
70.
I. Moroni, L. D’incerti, E. Maccagnano, M. Bugiani, M. Rimoldi, G. Broggi, G. Uziel, L-2-hydroxyglutaric aciduria and brain malignant tumors. J. Inherit. Metab. Dis. 25, 59 (2002)
71.
A.M. Intlekofer, R.G. Dematteo, S. Venneti, L.W. Finley, C. Lu, A.R. Judkins, A.S. Rustenburg, P.B. Grinaway, J.D. Chodera, J.R. Cross, Hypoxia induces production of L-2-hydroxyglutarate. Cell. Metab. 22, 304–311 (2015)CrossRefPubMedPubMedCentral
72.
F.E. Bleeker, S. Lamba, S. Leenstra, D. Troost, T. Hulsebos, W.P. Vandertop, M. Frattini, F. Molinari, M. Knowles, A. Cerrato, IDH1 mutations at residue p. R132 (IDH1R132) occur frequently in high‐grade gliomas but not in other solid tumors. Hum. Mutat. 30, 7–11 (2009)CrossRefPubMed
73.
A.K. Murugan, E. Bojdani, M. Xing, Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochem. Biophys. Res. Commun. 393, 555–559 (2010)CrossRefPubMedPubMedCentral
74.
R.S. Haber, K.R. Weiser, A. Pritsker, I. Reder, D.E. Burstein, GLUT1 glucose transporter expression in benign and malignant thyroid nodules. Thyroid. 7, 363–367 (1997)CrossRefPubMed
75.
K. Matsuzu, F. Segade, U. Matsuzu, A. Carter, D.W. Bowden, N.D. Perrier, Differential expression of glucose transporters in normal and pathologic thyroid tissue. Thyroid. 14, 806–812 (2004)CrossRefPubMed
76.
J.H. Nahm, H.M. Kim, J.S. Koo, Glycolysis-related protein expression in thyroid cancer. Tumor Biology 39, 1010428317695922 (2017)CrossRefPubMed
77.
J.E. Wilson, Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J. Exp. Biol. 206, 2049–2057 (2003)CrossRefPubMed
78.
Paweł. Lis, Mariusz Dyl ag, Katarzyna Nied´zwiecka, YoungH. Ko, PeterL. Pedersen AG, S. Ułaszewski, The HK2 dependent “Warburg Effect” and mitochondrial oxidative phosphorylation in cancer: targets for effective therapy with 3-bromopyruvate. Molecules 21, 1730 (2016)CrossRefPubMedCentral
79.
G. Rijksen, R. Oskam, C.F. Molthoff, S.-J.L. On, M. Streefkerk, G.E. Staal, Hexokinase isoenzymes from anaplastic and differentiated medullary thyroid carcinoma in the rat. Eur. J. Cancer 20, 967–973 (1984)CrossRef
80.
L. Hooft, A. Van der Veldt, P. Van Diest, O. Hoekstra, J. Berkhof, G. Teule, C. Molthoff, [18F] fluorodeoxyglucose uptake in recurrent thyroid cancer is related to hexokinase I expression in the primary tumor. J. Clin. Endocrinol. Metab. 90, 328–334 (2005)CrossRefPubMed
81.
L. Hooft, A. Van Der Veldt, O. Hoekstra, M. Boers, C. Molthoff, P. Van Diest, Hexokinase III, cyclin A and galectin‐3 are overexpressed in malignant follicular thyroid nodules. Clin. Endocrinol. (Oxf). 68, 252–257 (2008)CrossRefPubMed
82.
K. Imamura, T. TANAKA, Multimolecular forms of pyruvate kinase from rat and other mammalian tissues. J. Biochem. 71, 1043–1051 (1972)CrossRefPubMed
83.
H.R. Christofk, M.G. Vander Heiden, M.H. Harris, A. Ramanathan, R.E. Gerszten, R. Wei, M.D. Fleming, S.L. Schreiber, L.C. Cantley, The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452, 230 (2008)CrossRefPubMed
84.
M.I. Koukourakis, A. Giatromanolaki, E. Sivridis, Lactate dehydrogenase isoenzymes 1 and 5: differential expression by neoplastic and stromal cells in non-small cell lung cancer and other epithelial malignant tumors. Tumor Biol. 24, 199–202 (2003)CrossRef
85.
C. Feng, Y. Gao, C. Wang, X. Yu, W. Zhang, H. Guan, Z. Shan, W. Teng, Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer. J. Clin. Endocrinol. Metab. 98, E1524–E1533 (2013)CrossRefPubMed
86.
V.R. Fantin, J. St-Pierre, P. Leder, Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 9, 425–434 (2006)CrossRefPubMed
87.
D. Mirebeau-Prunier, S. Le Pennec, C. Jacques, J.-F. Fontaine, N. Gueguen, N. Boutet-Bouzamondo, A. Donnart, Y. Malthièry, F. Savagner, Estrogen-related receptor alpha modulates lactate dehydrogenase activity in thyroid tumors. PLoS ONE. 8, e58683 (2013)CrossRefPubMedPubMedCentral
88.
P. Kachel, B. Trojanowicz, C. Sekulla, H. Prenzel, H. Dralle, C. Hoang-Vu, Phosphorylation of pyruvate kinase M2 and lactate dehydrogenase A by fibroblast growth factor receptor 1 in benign and malignant thyroid tissue. BMC. Cancer 15, 140 (2015)CrossRefPubMedPubMedCentral
89.
A.P. Halestrap, The SLC16 gene family–structure, role and regulation in health and disease. Mol. Aspects. Med. 34, 337–349 (2013)CrossRefPubMed
90.
A.P. Halestrap, M.C. Wilson, The monocarboxylate transporter family—role and regulation. IUBMB Life 64, 109–119 (2012)CrossRefPubMed
91.
C. Pinheiro, A. Longatto-Filho, J. Azevedo-Silva, M. Casal, F.C. Schmitt, F. Baltazar, Role of monocarboxylate transporters in human cancers: state of the art. J. Bioenerg. Biomembr. 44, 127–139 (2012)CrossRefPubMed
92.
J.M. Johnson, S.Y. Lai, P. Cotzia, D. Cognetti, A. Luginbuhl, E.A. Pribitkin, T. Zhan, M. Mollaee, M. Domingo-Vidal, Y. Chen, Mitochondrial Metabolism as a Treatment Target in Anaplastic Thyroid Cancer. Semin Oncol. 42, 915–922 (2015)CrossRefPubMedPubMedCentral
93.
J.M. Curry, P. Tassone, P. Cotzia, J. Sprandio, A. Luginbuhl, D.M. Cognetti, M. Mollaee, M. Domingo‐Vidal, E.A. Pribitkin, W.M. Keane, Multicompartment metabolism in papillary thyroid cancer. Laryngoscope 126, 2410–2418 (2016)CrossRefPubMed
94.
R.J. DeBerardinis, T. Cheng, Q’s next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29, 313 (2010)CrossRefPubMed
95.
C.L. Collins, M. Wasa, W.W. Souba, S.F. Abcouwer, Regulation of glutamine synthetase in human breast carcinoma cells and experimental tumors. Surgery 122, 451–464 (1997)CrossRefPubMed
96.
E. Friday, R. Oliver, T. Welbourne, F. Turturro, Glutaminolysis and glycolysis regulation by troglitazone in breast cancer cells: Relationship to mitochondrial membrane potential. J. Cell. Physiol. 226, 511–519 (2011)CrossRefPubMed
97.
H.M. Kim, Y.K. Lee, J.S. Koo, Expression of glutamine metabolism-related proteins in thyroid cancer. Oncotarget 7, 53628 (2016)PubMedPubMedCentral
98.
Y. Yu, X. Yu, C. Fan, H. Wang, R. Wang, C. Feng, H. Guan, Targeting glutaminase-mediated glutamine dependence in papillary thyroid cancer. J. Mol. Med. 96, 777–790 (2018)CrossRefPubMed
99.
J.-w Kim, P. Gao, Y.-C. Liu, G.L. Semenza, C.V. Dang, Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol. Cell. Biol. 27, 7381–7393 (2007)CrossRefPubMedPubMedCentral
100.
H. Shim, C. Dolde, B.C. Lewis, C.-S. Wu, G. Dang, R.A. Jungmann, R. Dalla-Favera, C.V. Dang, c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc. Natl. Acad. Sci. 94, 6658–6663 (1997)CrossRefPubMedPubMedCentral
101.
Y. Qu, Q. Yang, J. Liu, B. Shi, M. Ji, G. Li, P. Hou, c-Myc is required for BRAFV600E-induced epigenetic silencing by H3K27me3 in tumorigenesis. Theranostics 7, 2092 (2017)CrossRefPubMedPubMedCentral
102.
J.-w Kim, I. Tchernyshyov, G.L. Semenza, C.V. Dang, HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 3, 177–185 (2006)CrossRefPubMed
103.
J. Pouysségur, F. Dayan, N.M. Mazure, Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441, 437 (2006)CrossRefPubMed
104.
C.V. Dang, Kim J-w, P. Gao, J. Yustein, The interplay between MYC and HIF in cancer. Nat. Rev. Cancer 8, 51 (2008)CrossRefPubMed
105.
J.D. Gordan, C.B. Thompson, M.C. Simon, HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell. 12, 108–113 (2007)CrossRefPubMedPubMedCentral
106.
O. Koperek, E. Akin, R. Asari, B. Niederle, N. Neuhold, Expression of hypoxia-inducible factor 1 alpha in papillary thyroid carcinoma is associated with desmoplastic stromal reaction and lymph node metastasis. Virchows. Arch. 463, 795–802 (2013)CrossRefPubMed
107.
A. Klaus, O. Fathi, T.-W. Tatjana, N. Bruno, K. Oskar, Expression of hypoxia-associated protein HIF-1α in follicular thyroid cancer is associated with distant metastasis. Pathol. Oncol. Res. 24, 289–296 (2018)CrossRefPubMed
108.
L. Lodewijk, P. van Diest, P. van der Groep, N. ter Hoeve, A. Schepers, J. Morreau, J. Bonenkamp, A. van Engen-van Grunsven, S. Kruijff, B. van Hemel, Expression of HIF-1α in medullary thyroid cancer identifies a subgroup with poor prognosis. Oncotarget 8, 28650 (2017)CrossRefPubMedPubMedCentral
109.
Y. Lv, Y. Sun, T. Shi, C. Shi, H. Qin, Z. Li, Pigment epithelium-derived factor has a role in the progression of papillary thyroid carcinoma by affecting the HIF1α-VEGF signaling pathway. Oncol. Lett. 12, 5217–5222 (2016)CrossRefPubMedPubMedCentral
110.
İ. Bingül, P. Vural, S. Doğru‐Abbasoğlu, E. Çil, M. Uysal, Vascular endothelial growth factor G + 405C polymorphism may contribute to the risk of developing papillary thyroid carcinoma. J. Clin. Lab. Anal. 31, e22110 (2017)CrossRef
111.
O. Baris, Fdr Savagner, Vr Nasser, Ba Loriod, S. Granjeaud, S. Guyetant, B. Franc, P. Rodien, V. Rohmer, Fo Bertucci, Transcriptional profiling reveals coordinated up-regulation of oxidative metabolism genes in thyroid oncocytic tumors. J. Clin. Endocrinol. Metab. 89, 994–1005 (2004)CrossRefPubMed
112.
113.
114.
C.A. Von Roemeling, L.A. Marlow, A.B. Pinkerton, A. Crist, J. Miller, H.W. Tun, R.C. Smallridge, J.A. Copland, Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target. J. Clin. Endocrinol. Metab. 100, E697–E709 (2015)CrossRef
Metadata
Title
Advances in metabolomics of thyroid cancer diagnosis and metabolic regulation
Publication date
01-07-2019
Published in
Endocrine / Issue 1/2019
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-019-01904-1

Other articles of this Issue 1/2019

Endocrine 1/2019 Go to the issue

Original Article

Comparison of stress response following microwave ablation and surgical resection of benign thyroid nodules

Original Article

Bone turnover is altered during 72 h of sleep restriction: a controlled laboratory study

Letter to the Editor

Reply to “Methodological issues in meta-analysis of the metformin effects on simple obesity”

Letter to the Editor

A rare hereditary and metastatic paraganglioma involved in both spermatic cord and testis

Meta-Analysis

Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials

Original Article

Comparison and preliminary discussion of the reasons for the differences in diagnostic performance and unnecessary FNA biopsies between the ACR TIRADS and 2015 ATA guidelines

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits